diabetes-congress-frankfurt-2019-keynote

6 / 6

Page 17
Joint Event
November 29-30, 2019 | Frankfurt, Germany
28th International Conference on 3rd International Conference on
Diabetes and Endocrinology Diabetes and Metabolism &
2
0
1
9 CONGRESS
DIABETES
2019
DIABETES
Journal of Diabetology | Volume 3
Notes:
Therapeutic armamentarium of T2DM has been rapidly
expanding over last decade & dipeptidyl peptidase
IV inhibitors (gliptins) have emerged as safe, efficacious,
durable class. In this same timeframe, ADA-EASD guidelines
have become more patient centric & the USFDA has given a
mandate to prove cardiovascular safety before marketing any
antidiabetic drug.
Teneligliptin is a very widely used drug for T2DM in India
since 2015. Therapeutic doses of teneligliptin(20 or 40 mg/
day) have not been known to alter the QT interval in ECG,
but, supratherapeutic doses(160mg/day) may prolong the
same. Similar observations are made with sitagliptin (50 or
100 mg/d safe-but-400mg/d may prolong QT interval). Since
prolongation of QT interval can increase risk of polymorphic
ventricular tachyarrythmia Torsade de Pointes, this scrutiny is
essential.
Since there is no devoted study to assess if routine doses of
teneligliptin(20 or 40mg/day) are safe with respect to effect
on QT interval, we undertook this exercise.
We selected 66 adult nonpregnant T2DM patients (age >18
yrs <65 yrs) who were gliptin naïve & on standard antidiabetic
treatment, but, uncontrolled(HbA1c>7%). Teneligliptin
20mg/day was added to therapy & if needed, doubled to
40mg/day. Other drugs were unchanged through the study
duration (unless compelling clinically). Baseline 12 lead ECG
was recorded & also within 120 minutes of the 1st, 15th &
90th day of teneligliptin. Glycemic parameters were recorded
alongwith other laboratory tests. QT interval was measured
for each of these 4 ECGs (baseline, day 1, day 15 & 90) & QTc
was calculated as per Bazett’s formula(QTc=QT/ sq root RR
interval).
It was observed that there was no increase in QT/QTc
interval after 3 months of teneligliptin treatment(along
with other antidiabetic drugs like glimepiride, pioglitazone,
metformin). The drug improved glycemic parameters &
without noteworthy adverse events. Larger studies & longer
observation periods may help in future.
Speaker Biography
Suhas Gopal Erande is a practicing consultant who is having own Diabetes
centre & Insulin Pump Clinic at Akshaya Hospital, India. He has been writing
Diabetes Patient Education books over 2 decades. Felicitated for social
services for diabetes by ‘Diabetes Mitra’ award. He has written academic
articles for physicians at National & International levels. Publications in
National& International journals.Hehasbeenwritingchapters intextbooks
over years. Invited for poster presentation on Intensive GlucoseMonitoring
in Bethesda Baltimore 2016 Diabetes Technology Society Meet Invited for
Global Diabetes Conference. For Diabetes in Women lecture in Prague
August 2017. His recently published studies Prevalence of depression in
T2DM in India(DEPTH study) & effect of teneligliptin on QT-QTc interval(Q
SET study) have got International acclaim.
e:
Suhas Gopal Erande
Diabetic Speciality Centre & Insulin Pump Centre Akshay Hospital, India
QT/QTc safety and efficacy evaluation of Teneligliptin in Indian type
2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET
study)